Fenbendazole
Veterinary anthelmintic (dewormer). Tubulin polymerization inhibitor. FDA-approved for animals. Human off-label use driven by the Joe Tippens cancer-adjunct protocol (fenbendazole + vitamin E succinate + curcumin + berberine). Stack catalogs for interaction safety — real CYP interactions when stacked with peptides.
This compound sits in research-grey territory. The caveats below carry more weight than for FDA-approved entries — read them.
Methyl N-(6-phenylsulfanyl-1H-benzimidazol-2-yl)carbamate. Benzimidazole class — same structural family as mebendazole (human-approved parasite drug). Mechanism: disrupts microtubule assembly by binding tubulin at the colchicine site, which also disrupts glucose uptake in cancer cells (GLUT transporter dependence). The Joe Tippens protocol (2019 viral story: stage 4 lung cancer, attributed complete response to fenbendazole + vitamin E) spread via social media and led to a cohort of thousands self-experimenting. Preclinical data (cell lines + animal models) shows antiproliferative activity; no published human RCT exists as of 2026-05-07. Stack's posture: document for interaction safety (CYP3A4/1A2 modulation + anticoagulant interaction), not promote for cancer.
Stack DOES NOT recommend fenbendazole for cancer treatment. The Joe Tippens case report is a single anecdote — the cohort of thousands self-experimenting does not constitute clinical evidence. Antiproliferative data is preclinical only; doses required in cell lines far exceed human-tolerable serum levels. REAL DRUG INTERACTIONS: fenbendazole modulates CYP1A2 + CYP3A4 — documented interactions with warfarin (potentiation), metronidazole (toxicity risk), and cyclosporine. Liver enzyme elevation reported in some human users at high doses. Veterinary-grade formulations (Panacur C) are not pharmaceutical-grade — impurity profiles are unknown for human use.
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
FDA-approved for veterinary use (dogs, livestock). NOT FDA-approved for human use. Not on 503A Bulks List. Human-labeled fenbendazole exists in Mexico and South Korea as a prescription antiparasitic (Pantelmin). US off-label use is technically legal to possess but the veterinary formulations are not pharmaceutical-grade for human consumption.
Distilled themes from named communities — Reddit threads, forums, creator commentary. Not direct quotes; not clinical evidence. Useful for calibrating expectations against what real self-experimenters report.
Cohort is almost exclusively cancer-adjacent users. Community splits sharply: Tippens-lineage users report anecdotal benefits and defend the protocol; oncology-familiar users consistently point to the absence of clinical evidence and the CYP interaction risk. Stack's posture matches the oncology-familiar side — document the compound and its real interactions, do not promote for cancer claims.